Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

Neumora Therapeutics, a leading biopharmaceutical company specializing in neuroscience drug development, has made a significant addition to its team with the appointment of Dr. Robert Lenz as Executive Vice President and Head of Research and Development. This appointment marks a major milestone for Neumora as it continues to redefine the field of neuroscience drug development.

Dr. Lenz brings with him a wealth of experience, having spent 20 years developing groundbreaking drugs in areas of high medical need. His expertise in neuroscience and successful execution of clinical trials make him an invaluable asset to Neumora as the company advances its innovative pipeline, including the Phase 3 KOASTAL program for navacaprant in Major Depressive Disorder (MDD).

Henry Gosebruch, CEO of Neumora, expressed his delight at welcoming Dr. Lenz to the team, highlighting his deep domain expertise and clinical trial success. Gosebruch believes that with Dr. Lenz’s leadership in research and development, combined with Neumora’s strong team and capabilities, the company is poised to pioneer a new era of medicines for brain disorders and make a real difference in the lives of patients.

Dr. Lenz’s impressive track record includes his role as Head of Global Development at Amgen, where he oversaw numerous interventional studies and played a key role in the development and approval of groundbreaking medicines such as TEZSPIRE®, AIMOVIG®, and DUOPA®. His contributions to the field have been widely recognized, and his appointment at Neumora further solidifies the company’s commitment to pushing the boundaries of neuroscience drug development.

Excited about joining Neumora, Dr. Lenz expressed his admiration for the company’s quality programs and novel mechanisms of action. He believes that Neumora’s pipeline holds great potential to positively impact patients living with brain disorders. With his extensive experience and expertise, Dr. Lenz is eager to lead Neumora’s research, clinical, and regulatory efforts, leveraging his knowledge to advance the company’s industry-leading neuropsychiatry and neurodegeneration programs.

Neumora Therapeutics, founded with the mission to confront the global brain disease crisis, is dedicated to developing innovative therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. With a pipeline consisting of seven clinical and preclinical neuroscience programs targeting underserved neuropsychiatric disorders and neurodegenerative diseases, Neumora is at the forefront of redefining neuroscience drug development.

Neumora’s work is supported by an integrated suite of translational, clinical, and computational tools, enabling precision medicine approaches. With operations in the Greater Boston Area and South San Francisco, Neumora is well-positioned to drive advancements in neuroscience and bring forth the next generation of novel therapies.

For more information about Neumora Therapeutics and its groundbreaking work, please visit their website at www.neumoratx.com. Stay updated on their latest developments by following them on Twitter: @NeumoraTx.

Investors and media inquiries can reach out to Helen Rubinstein at (315) 382-3979 or Helen.Rubinstein@neumoratx.com. Media inquiries can also be directed to Katie Engleman at Katie@1abmedia.com.

In conclusion, Neumora Therapeutics’ appointment of Dr. Robert Lenz as Executive Vice President and Head of Research and Development marks an exciting chapter for the company. With Dr. Lenz’s expertise and leadership, combined with Neumora’s innovative pipeline, the future looks promising for the development of groundbreaking therapies that will revolutionize the treatment of brain disorders.